Contrasting Acrivon Therapeutics (NASDAQ:ACRV) and Biomea Fusion (NASDAQ:BMEA)

Biomea Fusion (NASDAQ:BMEA) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for Biomea Fusion and Acrivon Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	0	2	8	2	3.00
Acrivon Therapeutics	0	0	6	0	3.00

Biomea Fusion presently has a consensus target price of $29.40, suggesting a potential upside of 152.36%. Acrivon Therapeutics has a consensus target price of $23.83, suggesting a potential upside of 188.89%. Given Acrivon Therapeutics’ higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Biomea Fusion.

Valuation & Earnings

This table compares Biomea Fusion and Acrivon Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$117.25 million	($3.57)	-3.26
Acrivon Therapeutics	N/A	N/A	-$60.39 million	($2.88)	-2.86

Biomea Fusion is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 27.6% of Biomea Fusion shares are owned by company insiders. Comparatively, 8.5% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Biomea Fusion and Acrivon Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-91.86%	-76.56%
Acrivon Therapeutics	N/A	-47.31%	-43.10%

Volatility & Risk

Biomea Fusion has a beta of -0.43, indicating that its share price is 143% less volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.

Summary

Acrivon Therapeutics beats Biomea Fusion on 7 of the 11 factors compared between the two stocks.

About Biomea Fusion

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.